2019/2020 MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis

Short Summary #8

Developed by the Mucositis Study Group

-----------------------------------------------------------------------

Detailed publication

**Oral cryotherapy for the management of oral mucositis**

Citation


Cryotherapy — hematological cancer — HSCT — prevention

- **Guideline category: Recommendation (LoE II)**
- **Guideline statement:** The panel recommends using oral cryotherapy to prevent oral mucositis in patients undergoing autologous HSCT when the conditioning includes high-dose melphalan.

Cryotherapy — solid tumors — CT with bolus 5-FU — prevention

- **Guideline category: Recommendation (LoE II)**
- **Guideline statement:** The panel recommends that patients receiving bolus 5-FU chemotherapy undergo 30 min of oral cryotherapy to prevent oral mucositis.

Cryotherapy — solid tumors — CT with short-term infusion and short half-life agents — prevention

- **Guideline category: No guideline possible (LoE III)**

Cryotherapy — H&N cancer — RT — prevention

- **Guideline category: no guideline possible (LoE III)**

Cryotherapy — solid cancer — CT — treatment

- **Guideline category: no guideline possible (LoE III)**

Cryotherapy — solid cancer — AT with 5-FU (continuous) — prevention
Guideline category: no guideline possible (LoE III)

Abbreviations
CT — Chemotherapy
H&N — Head & neck
HSCT — Hematopoietic stem cell transplantation
LoE — Level of evidence
RT — Radiotherapy